Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Second-Line Nivolumab Data in mUC Show Efficacy as FDA Considers Approval

October 9th 2016

Safety, efficacy, and biomarker results from the phase II CheckMate-275 trial of the PD-1 inhibitor nivolumab (Opdivo) that support FDA and European Medicines Agency applications were reported at the 2016 ESMO Congress.

Targeted Treatments Still King in Kidney Cancer, Novel Combinations on the Horizon

October 4th 2016

In kidney cancer there are three “eras” in the history of treatment advances, said James Hsieh, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center.

Dr. Sweis on Trend Toward Immunotherapy in GU Malignancies

October 3rd 2016

Randy F. Sweis, MD, clinical instructor, University of Chicago Medicine, discusses the trend toward immunotherapy in the field of genitourinary malignancies.

Patient Preference Among Key Considerations in Frontline RCC Therapy

October 3rd 2016

Historically, patients with advanced renal cell carcinoma have had few treatment options, but several targeted agents and one immunotherapy, the checkpoint inhibitor nivolumab, have been approved within the past 5 years, considerably expanding the RCC treatment arsenal. In the frontline setting, targeted agents are often the go-to therapy.

Expert Discusses Immense Impact of Immunotherapy in GU Cancers

September 21st 2016

Elizabeth Plimack, MD, discusses some of the most impressive advancements with immunotherapy agents in the fields of renal cell carcinoma and bladder cancer, as well as remaining questions with the use of these treatments.

EMA Initiates Official Review of Nivolumab in Bladder Cancer

September 20th 2016

The European Medicines Agency has validated a type II variation application for use of nivolumab (Opdivo) as a treatment for patients with locally advanced unresectable or metastatic urothelial carcinoma who have progressed following platinum-based chemotherapy.

EC Approves Lenvatinib/Everolimus Combo for RCC

September 16th 2016

The European Commission has approved lenvatinib (Kisplyx) in combination with everolimus for patients with advanced renal cell carcinoma following 1 prior VEGF-targeted therapy.

Expert Discusses Impact of Atezolizumab in Advanced Bladder Cancer

September 15th 2016

The PD-L1 inhibitor atezolizumab has been found to be non-toxic and has demonstrated a major survival advantage in patients with metastatic urothelial bladder cancer.

EC Approves Cabozantinib for Renal Cell Carcinoma

September 15th 2016

The European Commission has approved cabozantinib for the treatment of patients with advanced renal cell carcinoma after the failure of VEGF-targeted therapy, according to Exelixis and Ipsen, the manufacturers of the multikinase inhibitor.

FDA Panel Votes Against Apaziquone in Bladder Cancer

September 14th 2016

The FDA’s Oncologic Drugs Advisory Committee voted 14-0 against approving apaziquone (EOquin; Qapzola) for intravesical instillation immediately following transurethral resection in patients with non-muscle invasive bladder cancer.

Exploring the "Dark Matter" in Prostate Cancer Genomics

September 14th 2016

Mark A. Rubin, MD, is an expert in prostate cancer genomics and pathology who has led key discoveries in the distinction between indolent and aggressive types of the malignancy.

Dr. Ball on Eventual Role of Immunotherapy in Patients With RCC

September 14th 2016

Mark Ball, MD, chief urology resident, Johns Hopkins University School of Medicine, discusses the eventual role that immunotherapy will play in the treatment landscape of renal cell carcinoma (RCC), as well as patient selection to receive immunotherapy as a single agent or in combination.

Obesity Paradox in RCC: Improved OS for Patients With High BMI

September 9th 2016

Evidence has demonstrated that obesity is a risk factor for clear cell renal cell carcinoma; however, a new report suggests that a high body mass index is a prognostic factor for improved survival in patients with metastatic RCC who have received targeted therapy.

Expert Discusses Evolving Roles of Cabozantinib, Nivolumab in RCC

September 8th 2016

Jorge A. Garcia, MD, discusses the final survival data from the phase III METEOR trial, which was the basis for cabozantinib's (Cabometyx's) FDA approval, as well as the role the agent will now play along with nivolumab (Opdivo) in advanced RCC.

Dr. McDermott on Major Findings of Efficacy and Safety of Nivolumab in RCC

September 7th 2016

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the findings of the phase III CheckMate-025 trial of nivolumab (Opdivo) versus everolimus (Afinitor) in renal cell carcinoma (RCC).

Dr. Rafii on Future Immunotherapy Approaches for Patients With Bladder Cancer

September 2nd 2016

Saeed Rafii, MD, PhD, medical director, Sarah Cannon Research Institute, United Kingdom, discusses novel immunotherapy approaches for the treatment of patients with bladder cancer.

Dr. Blute on Kidney-Sparing Surgery Vs Radical Nephrectomy in RCC

September 1st 2016

Michael L. Blute, MD, chair of Department of Urology, Massachusetts General Hospital, discusses the differences between kidney-sparing surgery and radical nephrectomy for patients with renal cell carcinoma (RCC).

Dr. Nanus on Clinical Trials Exploring Immunotherapy in Bladder Cancer

August 29th 2016

David M. Nanus, MD, medical oncologist, Weill Cornell Medicine and NewYork-Presbyterian Hospital, discusses ongoing clinical trials exploring immunotherapy agents for the treatment of patients with bladder cancer.

Dr. Poch on Nivolumab as a Treatment for Patients With Bladder Cancer

August 26th 2016

Michael A. Poch, MD, urologist and assistant member at Moffitt Cancer Center, discusses the potential of nivolumab (Opdivo) as a treatment for patients with metastatic bladder cancer.

Dr. Lee on Nanotechnology Combination Therapy in RCC

August 24th 2016

Benjamin R. Lee, MD, chief, Division of Urology, University of Arizona College of Medicine-Tucson Department of Surgery, and director of the Genitourinary Cancer and Disease Oriented Strategic Planning Team, University of Arizona Cancer Center, discusses nanotechnology combination therapy for patients with renal cell carcinoma (RCC).